核苷酸切除修复是多发性骨髓瘤的潜在治疗靶点
本研究评估核苷酸切除修复(NER)在多发性骨髓瘤(MM)中对烷化剂敏感性的作用。功能性检测显示MM细胞系和患者样本NER效率存在异质性;新诊断MM患者中ERCC3表达显著影响烷化剂治疗后的结局。抑制NER(尤其靶向XPB)可增加烷化剂敏感性并克服耐药,XPB抑制同时抑制NER和转录。
要点
- MM细胞系和患者样本中NER效率呈现异质性
- ERCC3表达显著影响接受烷化剂治疗的新诊断MM患者结局
- 抑制XPB可同时抑制NER和转录,增加烷化剂敏感性并克服耐药
核心结论
- NER影响骨髓瘤细胞对烷化剂的敏感性,ERCC3是MM的潜在治疗靶点。
研究设计与样本
- 研究使用新型功能性检测评估MM细胞系和患者样本的NER活性,并利用小RNA干扰、稳定敲低和过表达以及靶向XPB的小分子抑制剂进行功能验证。
主要发现
- MM细胞系和患者样本中NER效率呈现异质性。
- 利用下一代测序数据发现,经典NER基因ERCC3的表达显著影响接受烷化剂治疗的新诊断MM患者的结局。
- 通过小RNA干扰、稳定敲低和过表达以及靶向XPB(由ERCC3编码的DNA解旋酶)的小分子抑制剂,证明抑制NER显著增加MM对烷化剂的敏感性并克服耐药。
- 抑制XPB导致NER和转录的双重抑制,在骨髓瘤细胞中尤其有效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the development of novel drugs, alkylating agents remain an important component of therapy in multiple myeloma (MM). DNA repair processes contribute towards sensitivity to alkylating agents and therefore we here evaluate the role of nucleotide excision repair (NER), which is involved in the removal of bulky adducts and DNA crosslinks in MM. We first evaluated NER activity using a novel functional assay and observed a heterogeneous NER efficiency in MM cell lines and patient samples. Using next-generation sequencing data, we identified that expression of the canonical NER gene, excision repair cross-complementation group 3 (ERCC3), significantly impacted the outcome in newly diagnosed MM patients treated with alkylating agents. Next, using small RNA interference, stable knockdown and overexpression, and small-molecule inhibitors targeting xeroderma pigmentosum complementation group B (XPB), the DNA helicase encoded by ERCC3, we demonstrate that NER inhibition significantly increases sensitivity and overcomes resistance to alkylating agents in MM. Moreover, inhibiting XPB leads to the dual inhibition of NER and transcription and is particularly efficient in myeloma cells. Altogether, we show that NER impacts alkylating agents sensitivity in myeloma cells and identify ERCC3 as a potential therapeutic target in MM.
引用
- Szalat R, Samur MK, Fulciniti M, et al. Nucleotide excision repair is a potential therapeutic target in multiple myeloma. Leukemia. 2017. PMID: 28588253. doi:10.1038/leu.2017.182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。